Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregabalin/riluzole - Neurodawn Pharmaceutical

Next Previous
Drug Profile

Pregabalin/riluzole - Neurodawn Pharmaceutical

Alternative Names: Riluzole/pregabalin - Neurodawn Pharmaceutical; Y 4; Y-4 - Neurodawn Pharmaceutical; Y-4 tablets

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Benzothiazoles; Gabapentinoids; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 19 May 2025 NeuroDawn and Beijing Tian Tan Hospital initiate enrolment in a phase I pharmacokinetic trial (In volunteers) in China (PO, Tablet) (NCT07013773)
  • 28 Mar 2025 NeuroDawn and Beijing Tian Tan Hospital initiate enrolment in a phase I pharmacokinetic trial in Healthy volunteers in China (PO, Tablet) (NCT06935721)
  • 04 Jan 2025 Phase-I clinical trials in Unspecified (In volunteers) in China (PO) (NCT06935682)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top